Sulfamonomethoxine (SMM, DS-36) Veterinary Grade API is a synthetic sulfonamide antibacterial belonging to the 6-methoxypyrimidine subclass. It is supplied as a white to off-white crystalline powder with the molecular formula C11H12N4O3S, a molecular weight of 280.30 g/mol, and CAS registry number 1220-83-3. The DS-36 designation identifies a controlled-particle-size grade released for further processing into tablets, injections, capsules, powders, granules, premix, and oral solutions. The free acid has very slight solubility in water and increasing solubility in dilute mineral acids and alkali hydroxides; accordingly, aqueous injectable and solution dosage forms generally use the sodium salt or a buffered co-solvent system, while solid oral forms use the free acid. The antibacterial mechanism is competitive inhibition of dihydropteroate synthase, which interrupts bacterial folate synthesis. The API is manufactured under ICH Q7 GMP for active pharmaceutical ingredients, with residual solvent controls aligned to ICH Q3C and release specifications applied to each batch. Because SMM is a long-acting sulfonamide, regional approvals often permit less frequent dosing than sulfadiazine or sulfamethoxazole; however, withdrawal periods and maximum residue limits are species-specific and must be established by the finished-product manufacturer.

For formulation development, the DS-36 grade is differentiated by three release properties: particle-size distribution, residual solvent profile, and related-substance control. The free acid is typically milled and sieved to a d90 of ≤75 µm for direct blend premix and powder applications, or to a d90 of ≤150 µm where a granulation step is planned. Milling is performed with impact or pin mills under controlled humidity; the product is then discharged through a screened rotary valve to limit agglomerate carryover. Because the API is photosensitive, packaging in opaque polyethylene-lined drums is used to reduce light-induced sulfonamide degradation. The DS-36 label specification includes assay on dried basis, loss on drying, residue on ignition, heavy metals, related substances, and residual solvent content. These are release tests, not stability assertions; finished-product manufacturers are responsible for in-use and shelf-life stability data.

What release specification boundaries are used for the DS-36 grade?

The table below lists representative release criteria for Sulfamonomethoxine, DS-36 veterinary grade. Acceptance limits are aligned with common veterinary pharmacopoeial expectations, but batch release must be confirmed against the applicable monograph and manufacturer’s current specification.

Analytical control for the DS-36 grade includes laser diffraction particle size measurement per ISO 13320 and bulk/tapped density measurement per USP <616>. The HPLC method uses a C18 column and UV detection; retention time of SMM is compared with a reference standard. Residual solvent testing by headspace gas chromatography follows USP <467> or Ph. Eur. 2.4.24. Loss on drying is conducted at 105°C, and residue on ignition is determined in a muffle furnace at 600°C. These test conditions are part of the manufacturer’s validated methods and should not be transferred to finished-product stability protocols without revalidation.

On production-scale solid oral lines, the main bottleneck is blend segregation rather than chemical instability. Sulfamonomethoxine free acid has a narrow particle-size distribution after milling, but when it is diluted into premix carriers or directly compressed tablet blends, density differences between API and lactose monohydrate, microcrystalline cellulose, or calcium carbonate can create particle stratification in bin blenders and tablet press feed frames. Horizontal IBC blenders require cycle times and fill volumes to be validated for each batch size; sampling from top, middle, and bottom thief probes is used to confirm blend uniformity before compression. For low-dose tablets and premixes, geometric dilution of SMM into a carrier with similar bulk density is standard practice. Direct compression is not preferred for high-dose SMM tablets because the free acid exhibits poor compactibility and flow; roller compaction or high-shear wet granulation is generally required. When wet granulation is used, aqueous binder systems containing povidone or pregelatinized starch are applied in a high-shear granulator, and the wet mass is dried in a fluid-bed dryer with product temperature controlled to avoid excessive fines generation. Tablet hardness and friability are measured using the finished-product test methods, with friability testing commonly performed per USP <1216>. Published data for this specific formulation configuration is limited, so drying endpoint is usually set by loss on drying and granule friability rather than by a universal temperature limit.

For powders and granules intended for oral solution reconstitution, the sodium salt may be preferred over the free acid because of solubilization requirements. In such formulations, the sodium salt is blended with buffering agents, sweeteners, and flavor powders under low-humidity conditions; the blend is then filled into sachets or bulk containers. The addition of sodium carbonate or sodium citrate is used to maintain alkaline pH after reconstitution. This step requires tight control of pack fill weight because the final dose is delivered as a volume after dissolution; overdosing and underdosing arise more often from segregation and fill variance than from API assay variation.

When injectable dosage forms require sodium salt conversion and terminal sterilization

When injectable dosage forms require sodium salt conversion and terminal sterilization, manufacturing control shifts from particle properties to solution clarity, pH stability, and endotoxin control. Sulfamonomethoxine free acid is not suitable for simple aqueous injection because of very slight water solubility. Formulators convert the free acid to the sodium salt by titration with sodium hydroxide or use the supplied sodium salt grade. The resulting solution is typically maintained at an alkaline pH, commonly between 8.0 and 9.5, to avoid precipitation of the free acid. The exact pH depends on concentration, co-solvent, and antioxidant system. Terminal moist-heat sterilization at 121°C for 15 min may be applied only when solution pH and stability data demonstrate acceptable degradation and color change; otherwise, aseptic filtration through a 0.22 µm membrane is used. In production, stainless steel or glass-lined vessels are preferred because prolonged contact with copper or iron can accelerate sulfonamide oxidation. The solution should be protected from light and sparged with nitrogen if oxygen-sensitive impurities are observed.

Bacterial endotoxin limits for injectable SMM solutions are not fixed by the API grade. They are calculated from the maximum total daily dose and the species-specific pyrogen threshold, using the K/M formula described in general pharmacopoeial chapters such as USP <85> and Ph. Eur. 2.6.14. Sterility testing follows the applicable pharmacopoeial chapter; validation of the sterilization or filtration process must address the alkaline pH and any co-solvent present. Filter validation includes bacterial retention, extractables evaluation, and assessment of SMM adsorption on membrane materials such as polyethersulfone or PVDF. Compatibility with divalent cations in diluents should be evaluated because sulfonamide sodium salts can form poorly soluble salts in solution. Particulate matter limits for injections are mandatory irrespective of the API assay.

Comparative pharmacokinetic data position SMM between the shorter-acting sulfadiazine class and the longer-acting sulfadimethoxine in some veterinary species, but the differences are species-dependent and not fully captured by a single half-life value. The 6-methoxy substituent on the pyrimidine ring slows excretion and reduces the frequency of administration compared with sulfadiazine and sulfamethoxazole in cattle, swine, and poultry. Sulfamethoxazole is normally formulated with trimethoprim at a 5:1 ratio for potentiated activity; SMM is often used as a single active in regional veterinary markets, although combinations with dihydrofolate reductase inhibitors exist where regulatory approvals allow. Sulfadiazine has a more established injectable suspension profile, while SMM sodium salt offers a soluble injection option under alkaline pH. Sulfadimethoxine is also long-acting but has higher protein binding and different residue depletion characteristics, so substitution between SMM and sulfadimethoxine cannot be made on the basis of equal dose or withdrawal period.

The free acid and its sodium salt do not share a single specification profile

The free acid and the sodium salt are not interchangeable release specifications, even though the active moiety is the same. The sodium salt grade requires additional control of solution pH, water content, and clarity after dissolution, while the free acid grade is controlled for particle size distribution relevant to solid dosage forms. The sodium salt can absorb atmospheric moisture and requires controlled low-humidity handling; the free acid is less hygroscopic but should still be protected from high humidity to avoid flow changes. Each batch should be sampled after container opening and re-qualified for water content if exposure exceeds the validated hold time. The free acid grade is released by HPLC assay on dried basis; the sodium salt may be controlled by assaying the salt and expressing assay as SMM content. Related substances in sodium salt can include free acid and hydrolytic degradation products; limits are set in the manufacturer’s specification. Residual solvents from salt formation must be controlled to ICH Q3C. Heavy metals are usually tested on both grades, with a limit of ≤20 ppm on the free acid and equal or tighter limits on the sodium salt where parenteral use is intended.

Sulfonamide selection in veterinary formulations: kinetic and processing separation

Sulfonamide selection in veterinary formulations is governed by both kinetic profile and manufacturing behavior. The table below separates the major actives by formulation entry point and processing difference.

The selection of SMM over sulfadiazine is commonly justified by longer dosing intervals and availability of the soluble sodium salt; however, process development must account for alkaline pH and photosensitivity. The final product must align with the applicable veterinary pharmacopoeial monograph and regional residue regulations. For tablet and premix applications, the controlled particle-size range of the DS-36 grade reduces blend segregation risk, but it does not remove the need for mix uniformity validation on the actual production equipment. For injection and solution applications, the sodium salt grade is not a direct substitute for the free acid and requires its own stability, compatibility, and endotoxin studies.

Storage of the DS-36 grade is specified as controlled room temperature in tightly closed, light-resistant containers. Incompatibilities include strong oxidizing agents, which degrade the sulfonamide group, and concentrated acidic solutions, which may precipitate the free acid from sodium salt solutions. Divalent cation-containing diluents should be assessed case by case. Once containers are opened, the API should be used within the validated in-use period and protected from humidity, light, and cross-contamination. The finished-product manufacturer retains responsibility for batch-specific stability, residue depletion, and withdrawal-period determinations.